Search results
Results from the WOW.Com Content Network
Rivaroxaban was patented in 2007 and approved for medical use in the United States in 2011. [10] It is available as a generic medication. [11] It is on the World Health Organization's List of Essential Medicines. [12] In 2022, it was the 90th most commonly prescribed medication in the United States, with more than 7 million prescriptions. [13] [14]
Antistasin, the first discovered naturally occurring direct Xa inhibitor Rivaroxaban, the first synthetic direct Xa inhibitor marketed as a drug Prior to the introduction of direct factor Xa inhibitors, vitamin K antagonists such as warfarin were the only oral anticoagulants for over 60 years, and together with heparin have been the main blood ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
It took nine months since Novartis (NVS) published results from a late-stage study of its multiple sclerosis pill, but the Swiss pharmaceutical finally announced Wednesday that the U.S. Food and ...
This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales.
The world's biggest cancer-drugs maker Roche (RHHBY) was dealt another setback Friday. The U.S. Food and Drug Administration rejected Roche's request for accelerated approval of its trastuzumab ...
rivaroxaban: anticoagulant: Xarelto 6589 6234 12 aflibercept: Eylea 6551 5830 13 infliximab: Remicade 5908 7152 14 Pneumococcal conjugate vaccine: Prevnar 13 Prevenar 13 5802 5601 15 ustekinumab: Stelara 5156 4011 16 pregabalin: epilepsy: Lyrica 4970 5065
(not approved) (many companies) Yes Generics, e.g., Duovir-N: lamivudine zidovudine: nevirapine (not approved) (many companies) Yes Truvada: emtricitabine tenofovir disoproxil: August 2, 2004 Gilead Sciences: No Atripla: emtricitabine tenofovir disoproxil efavirenz: July 12, 2006 Gilead Sciences Bristol-Myers Squibb: Yes Complera (US) Eviplera ...